About CLS
News and insights
©Copyright 2024 CLS AB. All rights reserved.
MM-2022-025/Rev2
Using Minimally Invasive Laser Ablation
The challenges in healthcare are many. At CLS we are committed to developing better therapies for use in cancer care and neurosurgery. We do this by providing tools for precise tissue ablation using heat generated by laser light. Our close collaboration with healthcare professionals ensures our products meet their requirements and seamlessly fits into hospital workflows. This enables more patients to be treated based on their specific diagnosis and needs. Carefully precise.
Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally – without damaging healthy tissue. The procedure is minimally invasive and thus gentle on the patient, who typically can return quickly to normal life.
A tumor or epileptogenic foci in the brain means major challenges – for the patient and for healthcare. When using laser ablation in neurosurgery the lesion is directly targeted and treated with high precision. The treatment spares healthy tissue and causes less side effects than surgery and chemotherapy.
The thermal effects on cells depend mainly on two factors – temperature and time. Research has shown that moderate heating of cancerous tumor cells during a long time will not only kill the targeted tumor itself, but also activate the immune system to attack cancer cells throughout the body.
Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed CLS TRANBERG® Thermal Therapy Systems – seamlessly integrated systems for laser ablation, with several options for real time monitoring and control of the treatment.
Last week we joined the 2024 Congress of Neurological Surgeons (CNS) meeting in Houston where our partner ClearPoint Neuro, Inc. exhibited the ClearPoint Prism® Neuro Laser Therapy System, powered by CLS. In addition to good booth traffic and customer discussions, we also took part in the scientific program providing the latest updates on the use of Laser Interstitial Thermal Therapy (LITT) in neurosurgery.
Both abstracts provide the latest insights into the clinical use of focal laser ablation for prostate cancer, contributing to the ongoing development of minimally invasive cancer therapies.
On the 29th of August, CLS organized a training camp for our European distributors within urology and their Clinical Applications Specialists. During two intense days in Turin, Italy, the team learned a lot about the treatment of localized prostate cancer using the CLS TRANBERG® product portfolio, both in theory and in practice.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
©Copyright 2024 CLS AB. All rights reserved.
MM-2022-025/Rev2